WASHINGTON (Reuters)—U.S. President Joe Biden and his fellow Democrats promised voters sweeping drug price reform in their signature social spending bill but agreed to move ahead with a far less ambitious proposal after facing opposition in Congress. The plan could still fail as hurdles remain to approving the broader spending package, known as “Build Back…
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
The Clinical Value of Antiphospholipid Antibodies in Patients with COVID-19
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
ACR Convergence 2021: Advocacy Successes & Challenges
The ACR’s advocacy efforts over the past year have helped put critical prior authorization and step therapy legislation in front of Congress. Learn more at ACR Convergence 2021.

RheumPAC Hosts Rep. Mariannette Miller-Meeks, MD, in a Conversation on Healthcare Legislation
Earlier this month, RheumPAC donors joined the Iowa representative, an ophthalmologist, for a virtual discussion about healthcare legislation and how it can help specialty providers and their patients.
Speak Up: Ask Congress to Block Medicare Reimbursement Cuts
Rheumatologists may need to downsize and restrict patient care if Congress doesn’t act to block significant cuts to Medicare reimbursement rates totaling 9.75% in 2022.

Ethics Forum: To Test or Not to Test?
“Maria” is a 54-year-old woman with seropositive rheumatoid arthritis, as well as hypertension and hyperlipidemia. She is a new patient in your clinic following a move across the country to live with her children on a farm in a rural area of the Midwest. At her first visit, three months ago, you and Maria agreed—through…

Lively, Practical Training at Advocacy 101
Amid spirited discussions on drug pricing and insurance challenges, participants got hands-on experience advocating for current bills regulating prior authorization and pharmacy benefit managers.

A Look Inside the Advocate Experience at Advocates for Arthritis
Eric Dein, MD, shared rheumatology perspectives with five congressional offices on Sept. 28 as part of the virtual Hill Day. Read his hour-by-hour account, including staffer education, legislative requests and prior authorization woes.
Nonserious Infection Rates with Biologics Used to Treat RA
Bechman et al. set out to describe the frequency and predictors of nonserious infections and compare incidence rates across biologic DMARDs. They found all bDMARDs are associated with a greater risk of nonserious infection, with differences observed between agents. Although unmeasured confounding must be considered, the magnitude of effect is large.

Inspired by Healthcare Disparities to Advocate for Change
Seeing the challenges her rural patients faced in accessing specialty care, Amanda Schnell, MD, was inspired to make advocacy an integral part of her work at the University of Alabama at Birmingham.
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 249
- Next Page »
